Jan 12 (Reuters) - Revvity said on Monday it expects its 2025 adjusted profit per share to exceed its forecast of $4.90 to $5, as the medical equipment maker benefits from renewed demand for contract research and diagnostics services.
The company's shares were up nearly 6% in extended trading.
Pharmaceutical companies have ramped up drug development in the U.S. amid evolving trade policies under President Donald Trump.
Revvity said it expects to report fourth-quarter revenue of around $772 million, above Wall Street estimates of $760.3 million, according to data compiled by LSEG.
It also expects annual revenue to grow 4% to $2.86 billion, above estimates of $2.84 billion.
The company will report its fourth-quarter and full year 2025 results on February 2.
(Reporting by Puyaan Singh in Bengaluru; Editing by Leroy Leo)
LATEST POSTS
- 1
Pick Your Favored kind of soup - 2Map shows more than 1,900 measles cases across U.S.
- 3The most effective method to Shake Hands Expertly: A Bit by bit Guide
- 4Instructions to Expand Your Smash 1500's Presentation: Tips and Deceives
- 5Moon fever hits DC as Artemis 2 rocket 'candle' lights up Washington Monument just 1 month before launch (photos)
- Vote In favor of Your Favored Treat
- The Quadrantid meteor shower peaks tonight, but will the full 'Wolf Moon' outshine the show?
- Mummified cheetahs found in Saudi caves shed light on lost populations
- 4 Must-Visit bar-b-que Eateries This Year
- An Extended time of Self-Reflection: Self-awareness through Journaling
- Cheetos and Doritos to launch new versions without artificial dyes
- 'No Kings' protests recap: More than 8 million turned out across all 50 states, organizers say
- Brazil's former President Jair Bolsonaro seeks house arrest for prison time citing health issues
- Figure out how to Separate Among Fledgling and Master Fender bender Legal counselors
